{
    "id": "0489",
    "question": "A 62-year-old man with a history of chronic bronchitis comes to the physician because of a 1-month history of worsening shortness of breath and cough productive of thick sputum. He smoked one pack of cigarettes daily for 20 years but quit 5 years ago. Physical examination shows an increased anteroposterior chest diameter and coarse crackles in the lower lung fields bilaterally. Treatment with a drug that directly antagonizes the effects of vagal stimulation on the airways is begun. Which of the following drugs was most likely started?",
    "options": {
        "A": "Fluticasone",
        "B": "Montelukast",
        "C": "Tiotropium",
        "D": "Cromolyn"
    },
    "answer": "C",
    "predict": "To solve this question, let's break down the information provided and analyze it step by step: 1. **Patient Profile**: A 62-year-old man with a history of chronic bronchitis, now presenting with worsening shortness of breath and cough productive of thick sputum. This suggests a chronic respiratory condition that may have progressed or worsened. 2. **Smoking History**: The patient smoked one pack of cigarettes daily for 20 years, but quit 5 years ago. While quitting smoking is beneficial, the patient's history of smoking is significant, indicating a high risk for chronic obstructive pulmonary disease (COPD). 3. **Physical Examination Findings**: The increased anteroposterior chest diameter and coarse crackles in the lower lung fields bilaterally suggest pulmonary hyperinflation and possible airway obstruction, which are characteristic of COPD. 4. **Treatment Goal**: The treatment aims to antagonize the effects of vagal stimulation on the airways. Vagal stimulation can lead to bronchoconstriction, which worsens airway obstruction in patients with COPD. 5. **Treatment Options**: - **A. Fluticasone**: A corticosteroid used to reduce inflammation in the airways. While useful in COPD management, it does not directly antagonize vagal stimulation. - **B. Montelukast**: A leukotriene receptor antagonist that reduces inflammation and airway responsiveness but does not directly affect vagal stimulation. - **C. Tiotropium**: An anticholinergic medication that directly antagonizes the effects of vagal stimulation on the airways, causing bronchodilation and reducing bronchoconstriction. - **D. Cromolyn**: A mast cell stabilizer that prevents the release of histamine and other mediators, reducing inflammation and airway responsiveness, but it does not directly antagonize vagal stimulation. Considering the need to directly antagonize the effects of vagal stimulation on the airways, the most likely drug started in this scenario is **C. Tiotropium**. ```json {\"step_by_step_thinking\": \"The patient presents with symptoms and physical examination findings consistent with worsening COPD. The goal of treatment is to antagonize the effects of vagal stimulation on the airways, which is directly achieved by Tiotropium. The other options do not directly address this specific mechanism of action.\", \"answer_choice\": \"C\"} ```",
    "snippets": [],
    "scores": [],
    "execution_time": 67.44366884231567
}